BeiGene (BGNE) IPO Opens Up 20%

Today's IPO for BeiGene (NASDAQ: BGNE) opened for trading at $28.97 after pricing of its initial public offering of 6,600,000 American Depositary Shares (ADS), each representing 13 of its ordinary shares, par value $0.0001 per share, at an initial public offering price of $24.00 per ADS.

Goldman, Sachs & Co., Morgan Stanley and Cowen and Company are acting as joint book-running managers. Baird is acting as co-manager of the offering.

BeiGene is a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics. With a team of 215+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and a lasting impact on cancer patients.

You May Also Be Interested In

• ShengShu Technology explores Hong Kong IPO for over $500 million
• Anthropic pre-IPO credit facility to climb past $10B target - Bloomberg
• Lyntris said to price IPO in lower half of range